A Combined In Vitro/In Silico Approach to Identifying Off-Target Receptor Toxicity

Abstract

SummaryMany xenobiotics can bind to off-target receptors and cause toxicity via the dysregulation of downstream transcription factors. Identification of subsequent off-target toxicity in these chemicals has often required extensive chemical testing in animal models. An alternative, integrated in vitro/in silico approach for predicting toxic off-target functional responses is presented to refine in vitro receptor identification and reduce the burden on in vivo testing. As part of the methodology, mathematical modeling is used to mechanistically describe processes that regulate transcriptional activity following receptor-ligand binding informed by transcription factor signaling assays. Critical reactions in the signaling cascade are identified to highlight potential perturbation points in the biochemical network that can guide and optimize additional in vitro testing. A physiologically based pharmacokinetic model provides information on the timing and localization of different levels of receptor activation informing whole-body toxic potential resulting from off-target binding.

Phenols, antioxidant and anticancer properties of three medicinal plants: in vitro and in silico evaluation

“…In addition to, caffeic acid exhibited a ratio of (72 -95%) regarding the correlated in vitro activity and in silico efficiency; these findings confirmed the predetermined cytotoxic activity of caffeic acid and can be taken as evidence to confirm the cytotoxic activity against the selected cancer cell-lines. This finding was in line with the recent trend that scientists usu-ally combining both in silico and in vitro approaches to identify and validate the potential biological activity of lead compound(s) at pre-clinical testing level [85][86][87].…”

The Trends and Future Prospective of In Silico Models from the Viewpoint of ADME Evaluation in Drug Discovery

“…Based on AOPs, respective ML models for MIE(s) or key events will help to guide decision making in drug discovery. Furthermore, following an in silico identification of MIE, toxic outcomes for MIE can be extrapolated to potential in vivo toxicity using a PBPK model drawing of the plasma concentration profile [132]. Given that plasma concentrations can be predicted by integrated in silico predictive models for ADME, integrated in silico approaches for ADMET can computationally describe toxicological outcomes.…”